NCT03733093Completed
PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Background: There are many people living with human immunodeficiency virus (HIV) infection in Liberia. Most experts consider HIV an epidemic there. Researchers want to collect health data from Liberians with HIV over several years. This may help HIV prevention and treatment programs in Liberia. Objective: To learn more about how HIV affects people in Liberia. Eligibility: People with HIV in Liberia Design: Participants will be screened with a blood sample. Participants will visit the study clinic about 10 times over 3 years. They will need to return to the clinic after some visits to get test results. The visits will be closer together during the first part of the study and less frequent later. At each study visit, participants will: * Have a brief physical exam * Answer questions about how they are feeling and what medicines they are taking * Have blood taken from an arm vein by a needle * Give urine samples Participants ages 12 years or older may be asked questions about HIV risk behaviors. These include sex practices and drug use. Participants ages 18 years or older may be asked how their HIV infection makes them feel emotionally. Participants may be asked to join a research substudy. This will be about tuberculosis (TB) testing in people with HIV. For this substudy, participants will have a TB skin test. A small amount of liquid will be injected under the skin on the arm. Participants will return to the clinic a few days later. The test area will be checked. They will get their test results.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1377 (actual)
- First submitted
- 6 Nov 2018
- Start date
- 22 Aug 2019
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Diseases
- Tuberculosis, HIV
- NCT number
- NCT03733093
What you commit to
- Study type: Observational
- Participants enrolled: 1377
- From 22 Aug 2019 to the primary completion date, 31 Dec 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Any condition that, in the opinion of the investigator, would compromise the safety of the study subject or staff, or would prevent proper conduct of the study.
Other
- Individuals meeting the following criterion will be excluded from study participation:
Criteria the registry did not label
- INCLUSION CRITERIA:
- Individuals of any age and gender must meet all of the following criteria to be eligible for study participation:
- HIV infection confirmed by HIV-1/2 enzyme-linked immunosorbent assay (ELISA) and confirmatory test or positive assay for HIV-1 pVL.
- Ability to provide informed consent.
- Willingness to allow storage of biological samples for research testing.
- Willingness to be followed by a participant tracker.
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| C.H. Rennie Hospital Coordinator of this site? Confirm its status | Kakata | Liberia | Unknown status |
| John F. Kennedy (JFK) Medical Center Coordinator of this site? Confirm its status | Monrovia | Liberia | Unknown status |
| Redemption Hospital Coordinator of this site? Confirm its status | Monrovia | Liberia | Unknown status |
| Duport Road Clinic Coordinator of this site? Confirm its status | Paynesville | Liberia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.